GSK (LON:GSK – Get Rating) was upgraded by analysts at Deutsche Bank Aktiengesellschaft to a “buy” rating in a report released on Friday, Marketbeat reports.
GSK has been the topic of a number of other reports. UBS Group set a GBX 1,245 ($15.29) price objective on shares of GSK in a research report on Wednesday, February 1st. Barclays restated an “equal weight” rating and issued a GBX 1,450 ($17.81) target price on shares of GSK in a research note on Thursday, February 2nd. Jefferies Financial Group set a GBX 1,575 ($19.34) target price on shares of GSK in a research note on Wednesday, February 1st. Shore Capital restated a “buy” rating on shares of GSK in a research note on Friday, February 24th. Finally, JPMorgan Chase & Co. set a GBX 1,400 ($17.19) target price on shares of GSK in a research note on Thursday, March 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, GSK has an average rating of “Hold” and an average price target of GBX 1,573.33 ($19.32).
GSK Trading Up 0.8 %
GSK stock traded up GBX 10.80 ($0.13) during midday trading on Friday, reaching GBX 1,438.80 ($17.67). The stock had a trading volume of 1,131,217 shares, compared to its average volume of 8,517,070. The company has a quick ratio of 0.73, a current ratio of 0.91 and a debt-to-equity ratio of 207.87. GSK has a 52-week low of GBX 1,280.92 ($15.73) and a 52-week high of GBX 2,280.50 ($28.01). The firm has a market cap of £58.85 billion, a price-to-earnings ratio of 1,286.49, a price-to-earnings-growth ratio of 1.08 and a beta of 0.27. The company has a fifty day moving average of GBX 1,434.07 and a 200 day moving average of GBX 1,404.49.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Bitcoin Might Better Than Bitcoin Stocks and ETFs,
- GameStop Shares Surge On Surprise Profit
- Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
- Want Diversified Upside in Biotechnology? Check out LABU
- 3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.